Table of Contents
CVS Health and its long-term care pharmacy subsidiary, Omnicare, have reached a settlement with the Justice Department carrying a $440 million floor. The settlement would resolve a false claims case that resulted in a nearly $950 million judgment, following a jury’s earlier determination that Omnicare was responsible for more than 3.3 million false claims.
Payment Terms of the Settlement
According to a July 1 filing in a Texas federal bankruptcy court, CVS would pay the Justice Department $130 million within two weeks of the deal being finalized as part of the settlement. Another $310 million would be due March 15, 2028, or guaranteed to be paid by CVS by March 31, 2028, if not paid by the debtors’ estates.
A Second Agreement With Creditors
A second agreement tied to the settlement releases CVS from potential fraudulent transfer claims connected to a $660 million member distribution made to CVS entities in 2023. This second component addresses a separate legal exposure beyond the original false claims judgment.
CVS’s Position on the Omnicare Settlement
“The agreements are not an admission of liability or wrongdoing, and were agreed upon to avoid the time and expense of further litigation,” a spokesperson told Becker’s on July 8, describing the settlement as resolving mutual claim and distribution issues arising out of Omnicare’s Chapter 11 case.
CVS Calls the Resolution a Successful Conclusion
The spokesperson added that CVS is pleased to put this matter behind it as part of a successful conclusion of the Chapter 11 case, framing the settlement as the closing chapter of a lengthy legal and financial process tied to the subsidiary.
The Broader Context Behind the CVS Omnicare Settlement
In May, CVS secured court approval to sell Omnicare to GenieRx, an investment firm partnership, with the transaction expected to close later in 2026. The settlement is directly tied to this pending sale, since the agreements are conditioned on the transaction moving forward as planned.
Court Approval Timeline
The agreements are conditioned on court approval on or before Aug. 15, with a hearing scheduled for Aug. 12. This tight timeline means the settlement could be finalized within weeks, assuming the bankruptcy court approves both the settlement terms and the underlying sale to GenieRx.
What the CVS Omnicare Settlement Means Going Forward
With the jury’s original judgment reduced to a negotiated settlement floor of $440 million, the settlement allows CVS to resolve a significant legal liability while proceeding with its planned exit from the long-term care pharmacy business through the GenieRx sale. The outcome offers a case study in how large false claims judgments can be renegotiated through bankruptcy proceedings when a parent company is also managing a broader corporate divestiture.
What to Watch Next
As the Aug. 12 hearing approaches, stakeholders will be watching whether the bankruptcy court approves the settlement as structured, and whether the GenieRx sale closes on schedule later in 2026, both of which are prerequisites for the settlement to take full effect.
A Pattern Across the Pharmacy Sector
The CVS Omnicare settlement also fits within a broader pattern of False Claims Act enforcement against long-term care and specialty pharmacy operators, where billing practices tied to institutionalized or vulnerable patient populations have drawn heightened regulatory scrutiny in recent years. As pharmacy benefit managers and long-term care providers continue facing pressure from both regulators and private litigants, settlements of this scale may prompt other operators in the space to reassess their own compliance and documentation practices well before facing similar litigation.
